Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.66 |
| ▸ | EGFR | P00533 | 11/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513557 | 0.85 | FLT3 (0.66) | FLT3EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL4510760 | 0.80 | CDK2 (0.49) | FLT3EGFRCCNT1CDK9 | |
| SCHEMBL4518391 | 0.79 | FLT3 (1.00) | FLT3EGFRHDAC1CCNT1CDK9 | |
| SCHEMBL2547336 | 0.76 | EGFR (0.71) | FLT3EGFRHDAC1CCNT1CDK9 | |
| SCHEMBL4517459 | 0.76 | FLT3 (0.75) | FLT3EGFRHDAC1CCNT1CDK9 | |
| SCHEMBL28637607 | 0.74 | EGFR (0.68) | FLT3EGFRHDAC1HDAC3HDAC4 | |
| SCHEMBL30129576 | 0.74 | EGFR (0.68) | FLT3EGFRHDAC1HDAC3HDAC4 | |
| SCHEMBL30129517 | 0.74 | EGFR (0.68) | FLT3EGFRHDAC1HDAC3HDAC4 | |
| SCHEMBL30129279 | 0.72 | MKNK2 (0.73) | FLT3EGFRHDAC1HDAC3HDAC4 | |
| SCHEMBL4499548 | 0.72 | FLT3 (0.61) | FLT3EGFRCCNT1CDK9MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | FLT3 91/4885EGFR 598/4885HDAC1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.